Global Celiac Disease Drugs Market Growth (Status and Outlook) 2023-2029

Global Celiac Disease Drugs Market Growth (Status and Outlook) 2023-2029

Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.

LPI (LP Information)' newest research report, the “Celiac Disease Drugs Industry Forecast” looks at past sales and reviews total world Celiac Disease Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Celiac Disease Drugs sales for 2023 through 2029. With Celiac Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Celiac Disease Drugs industry.

This Insight Report provides a comprehensive analysis of the global Celiac Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Celiac Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Celiac Disease Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Celiac Disease Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Celiac Disease Drugs.

The global Celiac Disease Drugs market size is projected to grow from US$ 584.3 million in 2022 to US$ 1596 million in 2029; it is expected to grow at a CAGR of 15.4% from 2023 to 2029.

United States market for Celiac Disease Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Celiac Disease Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Celiac Disease Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Celiac Disease Drugs players cover Roche, Merck, Johnson & Johnson, BiolineRx, Pfizer, Innovate Biopharmaceuticals, ImmusanT, Novartis and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Celiac Disease Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
First Line of Treatment
Second Line of Treatment

Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Merck
Johnson & Johnson
BiolineRx
Pfizer
Innovate Biopharmaceuticals
ImmusanT
Novartis
Bristol-Myers Squibb
Immunomedics

Please note: The report will take approximately 2 business days to prepare and deliver.